Lawsuit against Janssen alleges Risperdal caused gynecomastia
Four men have filed separate personal injury lawsuits alleging that an antipsychotic medication was both defective and dangerous following the plaintiffs’ development of gynecomastia, according to a press release.
The complaints stem from patients living in Connecticut, Florida, Maryland and Ohio who claimed the administration of risperidone (Risperdal, Janssen Pharmaceuticals) at a young age led to gynecomastia, according to the release issued by Lieff Cabraser Heimann & Bernstein, LLP. The litigation was filed in state court in Pennsylvania and also named Johnson & Johnson, parent company to Janssen, as a defendant.
“The bodies of these young men have been permanently mutated by Risperdal,” attorney Wendy R. Fleishman, said in the release. “In a young man who is already isolated by his challenges caused by mental issues, the growth of women’s breasts on his body in adolescent and teenage years is absolutely devastating.
“As alleged in the complaint, Janssen knew Risperdal stimulated male breast development and failed to adequately warn physicians, parents, and the adolescents prescribed Risperdal of this side effect. So when the moms and dads gave their consent to add this prescription for their sons, they knew nothing about the potential horrible harm it could cause.”
Healio Psychiatry contacted Janssen for commentary, but has not received a reply. Check back soon for any further updates